Cargando…

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

BACKGROUND: To observe efficacy of the anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoid leukemia (B-ALL) patients whose disease did not reach CR or progressed again after a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Haibo, Deng, Haobin, Mu, Juan, Lyu, Cuicui, Jiang, Yanyu, Deng, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259947/ https://www.ncbi.nlm.nih.gov/pubmed/34239307 http://dx.doi.org/10.2147/OTT.S312904

Ejemplares similares

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
por: Liu, Meijing, et al.
Publicado: (2021)

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
por: Qi, Yao, et al.
Publicado: (2023)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
por: Lyu, Cuicui, et al.
Publicado: (2021)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
por: Deng, Haobin, et al.
Publicado: (2021)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
por: Liu, Pengjiang, et al.
Publicado: (2020)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
por: He, Xiaoyuan, et al.
Publicado: (2019)

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
por: Zhang, Yu, et al.
Publicado: (2022)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
por: Sheikh, Semira, et al.
Publicado: (2021)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
por: Jain, Michael D, et al.
Publicado: (2018)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ru9j7vj6a0akg55hoel8l1f28p